HEB - Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection. The commercial focus for Ampligen includes application as a treatment for chronic fatigue syndrome (CFS) and as an influenza vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development. Alferon N Injection is the United States Food and Drug Administration (FDA) approved product with an indication for refractory or recurring genital warts.